Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Gel Coat Biomaterials has developed a proprietary amoeba hydrogel platform that stabilizes enzymes, cells, and biological tissues. This technology enables longer-lasting function under harsh conditions (e.g., high temperature or in vivo), improves the pharmacokinetics of biopharmaceuticals by preventing degradation, supports more efficient API manufacturing via enzyme immobilization, and allows new applications such as implantable medical devices powered by stabilized bio-materials. The company has filed patents related to its hydrogel technologies and was recognized as a top biotech company in APAC by Life Sciences Review APAC's December 2024 issue.[8]
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Gel Coat Biomaterials, Inc..